«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

25卷

期数:

2019年05期

页码:

484-487

栏目:

临床医学

出版日期:

2019-09-20

文章信息/Info

Title:

Effects of PPI combined with FOLFOX regimen on postoperative intestinal mucosal barrier function and quality of life in patients with colon cancer

文章编号:

1006-8147(2019)05-0484-04

作者:

张明惠; 杨丹丹; 姚光琳

（河南省直第三人民医院内科，郑州450000）

Author(s):

ZHANG Ming-hui;  YANG Dan-dan;  YAO Guang-lin

（Department of Medicine, Henan Provincial Third People’s Hospital， Zhengzhou 450000, China）

关键词:

质子泵抑制剂; FOLFOX方案; 结肠癌根治术; 奥美拉唑

Keywords:

proton pump inhibitor;  FOLFOX Protocol;  colon cancer radical surgery;  omeprazole

分类号:

R735.3+5

DOI:

-

文献标志码:

A

摘要:

目的：探讨质子泵抑制剂（PPI）联合奥沙利铂+亚叶酸钙+氟尿嘧啶（FOLFOX方案）在结肠癌根治术后辅助化疗期间应用的价值。方法： 选取我院2015年3月-2017年3月收集的110例结肠癌患者，所有患者均接受结肠癌根治手术，采用随机数字表法分为观察组和对照组各55例；对照组术后接受FOLFOX方案化疗,观察组术后采用奥美拉唑联合FOLFOX方案治疗，对比两组化疗前、化疗结束时的二胺氧化酶（DAO）、血乳酸、尿乳果糖/甘露醇（L/M）、生存质量、各类化疗毒副反应发生率。结果: 治疗前，观察组和对照组的血清DAO、血乳酸、L/M水平差异不具有统计学意义（P>0.05）；治疗后，观察组患者的血清DAO、血乳酸、L/M水平均低于对照组（P<0.05），两组患者治疗后的血清DAO、血乳酸、L/M水平较治疗前均显著的升高（P<0.05）；治疗前，观察组和对照组的各维度生存质量评分差异无统计学意义（P>0.05）；治疗后，观察组患者的躯体功能、角色功能、认知功能、社会功能、整体生活质量评分均高于对照组（P<0.05），观察组的疲乏、恶心/呕吐、呼吸困难、失眠、食欲丧失、腹泻评分低于对照组（P<0.05）；观察组患者的腹泻、恶心/呕吐发生率显著低于对照组（P<0.05），两组患者的脱发、骨髓抑制、肝肾损害发生率差异无统计学意义（P>0.05）。结论: PPI联合FOLFOX方案在结肠癌根治术后应用较单纯化疗有利于减轻患者的不良反应，保护肠道功能，提高患者的生存质量。

Abstract:

Objective: To investigate the value of proton pump inhibitor(PPI) combined with oxaliplatin ,leucovorin and 5-fluorouracil (FOLFOX) in the treatment of colon cancer. Methods: One hundred and ten patients with colon cancer from March 2015 to March 2017 were enrolled. All patients underwent radical surgery for colon cancer. They were randomly divided into observation group and control group (55 cases). The FOLFOX regimen was treated with omeprazole and FOLFOX in the observation group. The diamine oxidase (DAO), blood lactate, and urinary fructose/mannitol (L/M) were compared before and after chemotherapy. Quality of life, the incidence of various types of chemotherapy toxic side effects were also compared. Results: Before treatment, serum DAO, blood lactate, and L/M levels in the study and control groups were not statistically different (P>0.05); after treatment, serum DAO, blood lactate, and L/M levels were significantly lower in the study group. In the control group, serum DAO, blood lactate, and L/M levels after treatment in both groups were significantly higher than before treatment (P<0.05); before treatment, between the dimensions of the study and control groups, the difference in quality of life scores was not statistically significant (P>0.05). After treatment, the physical function, role function, cognitive function, social function, and overall quality of life scores were higher in the study group than in the control group (P<0.05). Fatigue, nausea, vomiting, dyspnea, insomnia, loss of appetite, and diarrhea were lower in the study group than in the control group (P<0.05). The incidence of diarrhea and nausea and vomiting was significantly lower in the study group than in the control group (P<0.05). There was no significant difference in the incidence of hair loss, myelosuppression, and liver and kidney damage between the two groups (P>0.05). Conclusion: The application of PPI combined with FOLFOX in the treatment of colon cancer after radical resection may contribute more to the reduction of patients' adverse reactions, protection of intestinal function, and improvement of patients’ quality of life.

参考文献/References:

[1] 梁鸿，张辉，田鹏，等. 艾迪联合FOLFOX4方案治疗Ⅲ期结肠癌患者术后效果观察[J]. 中华实用诊断与治疗杂志,2016,30(2):196
[2] 秦琼，杨林，孙永琨，等. 老年结肠癌患者根治术后辅助化疗疗效及影响预后的多因素分析[J]. 中华老年医学杂志,2016,35(3):296
[3] 郑桁，张伟，王康. 完整肠系膜切除术治疗Ⅲ期结肠癌的效果及安全性分析[J]. 中国普通外科杂志,2016,25(4):487
[4] 刘光艺，黄镇，王子卫. 第8版国际抗癌联盟和美国癌症联合委员会胃癌TNM分期系统简介及解读[J]. 腹部外科,2017,30(4):241
[5] 祝朝富. FOLFOX4方案联合小牛脾提取物注射液对结肠癌术后患者临床疗效评价[J]. 中国中西医结合消化杂志,2017,25(3):191
[6] Huang C, Huang M, Ma C, et al. Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer[J]. Rad Oncol,2017,12(1):45
[7] 翟蒙蒙，李志刚，沈杰，等. 质子泵抑制剂对进展期胃癌化疗方案临床疗效的影响[J]. 中国临床药理学与治疗学,2017,22(8):933
[8] 赵加应，蔡元坤，殷琛庆，等. 奥美拉唑联合FOLFOX方案应用于结肠癌根治术后辅助化疗的疗效研究[J]. 中华普通外科杂志,2015,30(8):650
[9] Tsai Y, Lin J, Chen W, et al. Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough[J]. Springer Plus,2016, 5(1):103
[10] Cespedes Feliciano E M, Lee V S, Prado C M, et al. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study[J]. Cancer,2017,123(24):4868
[11] Ji W B, Hong K D, Kim J, et al. Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer[J]. Chemotherapy,2018,63(1):8
[12] 唐承薇，马骁，黄志寅. 质子泵抑制剂与肠道微生态[J]. 中华消化杂志,2016,36(2):139
[13] 雷招宝. 关注质子泵抑制剂的不良反应与合理用药[J]. 世界华人消化杂志,2016,24(23):3468
[14] 贝宴屏，张欢乐，陆妙珍. 不同辅助化疗方案治疗结肠癌的疗效比较[J]. 中国现代医生,2017,55(6):82
[15] 史晓晓，郑松柏. 质子泵抑制剂长期应用的安全性研究进展[J]. 中国新药与临床杂志,2016,35(6):387

相似文献/References:

[1]宋明伟,姜 葵.质子泵抑制剂与小肠细菌过生长关系的研究[J].天津医科大学学报,2014,20(06):445.
　SONG Ming-wei,JIANG Kui.Relationship between the proton pump inhibitors and small intestinal bacterial overgrowth[J].Journal of Tianjin Medical University,2014,20(05):445.

备注/Memo

备注/Memo:

作者简介 张明惠（1979-），女，主治医师，硕士， 研究方向：临床内科；E-mail: tigchina@163.com。

常用功能

更新日期/Last Update: 2019-10-11